XML 20 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Aug. 31, 2022
Aug. 31, 2021
Current Assets:    
Cash and cash equivalents $ 2,178,687 $ 8,293,162
Accounts receivable, net 1,017,405 1,468,429
Inventory, net 879,033 339,385
Other receivables, current portion 1,085,335 814,157
Prepaid expenses and other current assets 571,335 218,376
Total current assets 5,731,795 11,133,509
Property and equipment, net 5,800,648 6,070,291
Intangible assets, net 18,840,619 32,029,499
Right-of-use assets, net 2,673,934 2,543,396
Other receivables, net of current portion 692,738
Goodwill 7,825,844 9,488,848
TOTAL ASSETS 40,872,840 61,958,281
Current Liabilities:    
Accounts payable 1,800,268 1,449,784
Accrued expenses 1,116,125 1,129,309
Accrued interest (including amounts to related parties) 454,189 366,280
Government loans and notes payable, current portion 4,485,649
Convertible notes payable, net of discount of $2,851,048 9,099,654
Contingent liability 534,595
Due to related parties 478,897 478,920
Finance lease liability, current portion 8,890 23,184
Operating lease liability, current portion 582,088 530,797
Total current liabilities 14,074,706 8,463,923
Debentures, related parties 946,250 982,205
Government loans and notes payable, net of current portion 161,460 5,133,604
Finance lease liability, net of current portion 12,076 16,217
Operating lease liability, net of current portion 2,185,329 2,057,805
Deferred tax liability 1,445,448 1,500,372
TOTAL LIABILITIES 18,825,269 18,154,126
Commitments and contingencies
Novo Integrated Sciences, Inc.    
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at August 31, 2022 and August 31, 2021, respectively
Common stock; $0.001 par value; 499,000,000 shares authorized; 31,180,603 and 26,610,144 shares issued and outstanding at August 31, 2022 and August 31, 2021, respectively 31,181 26,610
Additional paid-in capital 66,056,824 54,579,396
Common stock to be issued (4,149,633 and 3,622,199 shares at August 31, 2022 and August 31, 2021) 9,474,807 9,236,607
Other comprehensive income 560,836 991,077
Accumulated deficit (53,818,489) (20,969,274)
Total Novo Integrated Sciences, Inc. stockholders’ equity 22,305,159 43,864,416
Noncontrolling interest (257,588) (60,261)
Total stockholders’ equity 22,047,571 43,804,155
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 40,872,840 $ 61,958,281